Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9422414 | 0.81 | CYP1A2 (0.33) | CYP1A2CYP1B1 | |
| SCHEMBL24437009 | 0.81 | CYP1A2 (0.33) | CYP1A2CYP1B1 | |
| SCHEMBL19297003 | 0.81 | CYP1A2 (0.33) | CYP1A2CYP1B1 | |
| SCHEMBL19814039 | 0.80 | CYP1A2 (0.39) | CYP1A2CYP1B1CYP1A1 | |
| SCHEMBL14281222 | 0.71 | CA1 (0.36) | CYP1A2CYP1B1CA1CA9CYP1A1 | |
| SCHEMBL12043463 | 0.71 | CYP2B6 (0.42) | CYP1A2CYP1B1CA1CA9CYP1A1 | |
| SCHEMBL8404603 | 0.71 | CYP1A2 (0.50) | CYP1A2CYP1B1CA1CA9CYP1A1 | |
| SCHEMBL8215841 | 0.71 | CYP1A2 (0.46) | CYP1A2CYP1B1CA1CA9CYP1A1 | |
| SCHEMBL8404587 | 0.71 | CYP1A2 (0.37) | CYP1A2CYP1B1CA1CA9CYP1A1 | |
| SCHEMBL1362915 | 0.70 | CA1 (0.34) | CYP1A2CYP1B1CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190284136-A1 | INDOLINE DERIVATIVES | VIIV HEALTHCARE UK LIMITED (GB) | 2019-09-19 | — | — | US | disclosed |
| WO-2018020357-A1 | INDOLINE DERIVATIVES | VIIV HEALTHCARE UK LIMITED (GB) | 2018-02-01 | — | — | WO | disclosed |
| US-9527828-B2 | Method for expanding hematopoietic stem cells using heterocyclic compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-12-27 | — | — | US | disclosed |
| US-9527828-B2 | Method for expanding hematopoietic stem cells using heterocyclic compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-12-27 | — | — | US | disclosed |
| EP-2218716-B1 | METHOD FOR AMPLIFYING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2016-11-16 | — | — | EP | disclosed |
| US-9328085-B2 | Heterocyclic compounds and expansion agents for hematopoietic stem cells | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-05-03 | — | — | US | disclosed |
| US-8895768-B2 | Cyclopara (hetero) arylene compound and method for producing same | KYOTO UNIVERSITY (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895768-B2 | Cyclopara (hetero) arylene compound and method for producing same | KYOTO UNIVERSITY (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20140227780-A1 | METHOD FOR PRODUCING MEGAKARYOCYTES AND/OR PLATELETS FROM PLURIPOTENT STEM CELLS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-08-14 | — | — | US | disclosed |
| US-20140227780-A1 | METHOD FOR PRODUCING MEGAKARYOCYTES AND/OR PLATELETS FROM PLURIPOTENT STEM CELLS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-08-14 | — | — | US | disclosed |
| US-20120220790-A1 | CYCLOPARA (HETERO) ARYLENE COMPOUND AND METHOD FOR PRODUCING SAME | KYOTO UNIVERSITY (JP) | 2012-08-30 | — | — | US | disclosed |
| EP-2484656-A1 | CYCLOPARA(HETERO)ARYLENE COMPOUND AND METHOD FOR PRODUCING SAME | Kyoto University (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-20120128640-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-20120128640-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| EP-2439204-A1 | HETEROCYCLIC COMPOUND AND HEMATOPOIETIC STEM CELL AMPLIFIER | Nissan Chemical Industries, Ltd. (JP) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010140685-A1 | HETEROCYCLIC COMPOUND AND HEMATOPOIETIC STEM CELL AMPLIFIER | 日産化学工業株式会社 (JP) | 2010-12-09 | — | — | WO | disclosed |
| US-20100266556-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100266556-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2218716-A1 | METHOD FOR AMPLIFYING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2010-08-18 | — | — | EP | disclosed |
| US-20080020148-A1 | Chromane Derivatives Method for Production and the Use Thereof | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120128640-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | HCLS1, RUNX1, RCC1 | CYP1A2 2162/4885CYP1B1 474/4885CA1 3645/4885 |
| US-20100266556-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | HCLS1, RUNX1, ACIN1 | CYP1A2 2808/4885CYP1B1 1090/4885CA1 4256/4885 |
| US-20120220790-A1 | CYCLOPARA (HETERO) ARYLENE COMPOUND AND METHOD FOR PRODUCING SAME | AHR, AR, CYP2A13 | CYP1A2 8/4885CYP1B1 14/4885CA1 2584/4885 |
| US-20080020148-A1 | Chromane Derivatives Method for Production and the Use Thereof | C1S, CHRM1, C1R | CYP1A2 39/4885CYP1B1 99/4885CA1 211/4885 |
| US-20190284136-A1 | INDOLINE DERIVATIVES | IRF3, EIF2AK2, MAVS | CYP1A2 362/4885CYP1B1 691/4885CA1 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.